Cost effectiveness of golimumab for the treatment of active psoriatic arthritis

Background Golimumab is a novel TNF-α inhibitor licensed to treat patients with active PsA. Although its clinical efficacy has been proven in clinical trials, its cost effectiveness is yet to be established.